Grit Biotechnology Reports the US FDA’s IND Approval of GT201 for Treating Advanced Solid Tumors
Shots:
- The US FDA has granted clearance to the company’s IND application for GT201 for treating advanced solid tumors. It received IND approval across China in Jul 2023
- GT201 is a genetically engineered TIL product developed using StemTexp and StaViral platforms. It enhances T cell survival through membrane-bound cytokine complex expression, improving tumor-killing efficacy and long-term survival
- Grit's another program, GT101 (non-gene-engineered TIL program), is under pivotal P-II clinical evaluation with its BLA planned in 2025
Ref: Grit Biotechnology | Image: Grit Biotechnology
Related News:- Zymeworks Reports the US FDA’s IND Clearance of ZW191 for Treating Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
